Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 4/20 | 0.46 |
| ▸ | CA2 | P00918 | 2/20 | 0.46 |
| ▸ | CA7 | P43166 | 2/20 | 0.46 |
| ▸ | CA9 | Q16790 | 2/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | TACR1 | P25103 | 2/20 | 0.41 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1663117 | 1.00 | CA1 (0.46) | CA1CA2CA7CA9TDP1 | |
| SCHEMBL1663119 | 1.00 | CA1 (0.46) | CA1CA2CA7CA9TDP1 | |
| SCHEMBL5519279 | 0.84 | CA1 (0.44) | CA1CA2CA7CA9TDP1 | |
| SCHEMBL5526171 | 0.84 | CA1 (0.44) | CA1CA2CA7CA9TDP1 | |
| SCHEMBL7631267 | 0.84 | TSHR (0.41) | CA1CA2CA7CA9TDP1 | |
| SCHEMBL1865158 | 0.84 | CA1 (0.56) | CA1CA2CA7CA9TSHR | |
| SCHEMBL14453897 | 0.84 | CA1 (0.56) | CA1CA2CA7CA9TSHR | |
| SCHEMBL18391961 | 0.84 | CA1 (0.46) | CA1CA2CA7CA9TDP1 | |
| SCHEMBL2878217 | 0.84 | CA1 (0.46) | CA1CA2CA7CA9TDP1 | |
| SCHEMBL2882825 | 0.83 | TDP1 (0.45) | CA1CA2CA7CA9TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12030904-B2 | Phospholipid compounds and uses thereof | GILEAD SCIENCES, INC. (US) | 2024-07-09 | — | — | US | disclosed |
| US-12030904-B2 | Phospholipid compounds and uses thereof | GILEAD SCIENCES, INC. (US) | 2024-07-09 | — | — | US | disclosed |
| US-20240025932-A1 | PHOSPHOLIPID COMPOUNDS AND USES THEREOF | GILEAD SCIENCES, INC. | 2024-01-25 | — | — | US | disclosed |
| US-20240025932-A1 | PHOSPHOLIPID COMPOUNDS AND USES THEREOF | GILEAD SCIENCES, INC. | 2024-01-25 | — | — | US | disclosed |
| US-11773122-B2 | Phospholipid compounds and uses thereof | GILEAD SCIENCES. INC. (US) | 2023-10-03 | — | — | US | disclosed |
| US-11773122-B2 | Phospholipid compounds and uses thereof | GILEAD SCIENCES. INC. (US) | 2023-10-03 | — | — | US | disclosed |
| US-20230250117-A1 | PHOSPHOLIPID COMPOUNDS AND USES THEREOF | GILEAD SCIENCES, INC. | 2023-08-10 | — | — | US | disclosed |
| US-20230250117-A1 | PHOSPHOLIPID COMPOUNDS AND USES THEREOF | GILEAD SCIENCES, INC. | 2023-08-10 | — | — | US | disclosed |
| US-20220081455-A1 | PHOSPHOLIPID COMPOUNDS AND USES THEREOF | GILEAD SCIENCES, INC. | 2022-03-17 | — | — | US | disclosed |
| US-20110092458-A1 | Use of (R)-Penciclovir Triphosphate for the Manufacture of a Medicament for the Treatment of Viral Diseases | NOVARTIS PHARMACEUTICALS CORPORATION | 2011-04-21 | — | — | US | disclosed |
| US-7045525-B1 | Use of (R)-peniciclovir triphosphate for the manufacture of a medicament for the treatment of viral diseases | NOVARTIS AG (CH) | 2006-05-16 | — | — | US | disclosed |
| US-20060069108-A1 | Use of (R)-penciclovir triphosphate for the manufacture of a medicament for the treatment of viral diseases | NOVARTIS PHARMACEUTICALS CORPORATION | 2006-03-30 | — | — | US | disclosed |
| EP-0822817-B1 | USE OF (R)-PENCICLOVIR TRIPHOSPHATE FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF VIRAL DISEASES | NOVARTIS INT PHARM LTD (BM) | 2003-07-23 | — | — | EP | disclosed |
| EP-0822817-A1 | USE OF (R)-PENCICLOVIR TRIPHOSPHATE FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF VIRAL DISEASES | SMITHKLINE BEECHAM PLC (GB) | 1998-02-11 | — | — | EP | disclosed |
| WO-1996033720-A1 | USE OF (R)-PENCICLOVIR TRIPHOSPHATE FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF VIRAL DISEASES | SMITHKLINE BEECHAM PLC (GB) | 1996-10-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110092458-A1 | Use of (R)-Penciclovir Triphosphate for the Manufacture of a Medicament for the Treatment of Viral Diseases | TYMP, PNP, HPRT1 | CA1 4570/4885CA2 3649/4885CA7 4643/4885 |
| US-12030904-B2 | Phospholipid compounds and uses thereof | PHOSPHO1, SGMS2, SGMS1 | CA1 3078/4885CA2 4188/4885CA7 3604/4885 |
| US-20230250117-A1 | PHOSPHOLIPID COMPOUNDS AND USES THEREOF | PHOSPHO1, SGMS2, SGMS1 | CA1 3078/4885CA2 4188/4885CA7 3604/4885 |
| US-20060069108-A1 | Use of (R)-penciclovir triphosphate for the manufacture of a medicament for the treatment of viral diseases | TYMP, PNP, HPRT1 | CA1 4570/4885CA2 3649/4885CA7 4643/4885 |
| US-20220081455-A1 | PHOSPHOLIPID COMPOUNDS AND USES THEREOF | PHOSPHO1, SGMS2, SGMS1 | CA1 3078/4885CA2 4188/4885CA7 3604/4885 |
| US-20240025932-A1 | PHOSPHOLIPID COMPOUNDS AND USES THEREOF | PHOSPHO1, SGMS2, SGMS1 | CA1 3078/4885CA2 4188/4885CA7 3604/4885 |
| US-11773122-B2 | Phospholipid compounds and uses thereof | PHOSPHO1, SGMS2, SGMS1 | CA1 3078/4885CA2 4188/4885CA7 3604/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.